VivoSeq
Oncology

Human Papilloma Virus Infection

7

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Human Papilloma Virus Infection is an early-stage landscape with 7 programs across 4 companies. The most active players are Iovance Biotherapeutics, Inc., Kura Oncology, Inc., Merck & Co.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2Sanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Protein / enzyme114%

Modality classified for 90% of 10 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase-3b, Partially Double-blind, Randomized, Multi-country Clinical Study to Evaluate the Immunogenicity,Safety, and Reactogenicity of SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
Active, not recruiting·SSerum Institute of India Pvt. Ltd.·Phase 3·NCT06281119·450 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)